Elliott J, Callingham B A, Barrand M A
Department of Pharmacology, University of Cambridge, UK.
J Pharm Pharmacol. 1989 Jan;41(1):37-41. doi: 10.1111/j.2042-7158.1989.tb06325.x.
One hour after MDL 72145 ((E)-2-(3',4'-dimethoxyphenyl)-3-fluoroallylamine) (2.5 mg kg-1) was given by intraperitoneal injection, the semicarbazide-sensitive amine oxidase (SSAO) activity of rat aorta and brown adipose tissue measured in-vitro was reduced by more than 95% of its control value, whereas the monoamine oxidase (MAO-A) activity remained virtually unaffected. The action of this drug on amine oxidases in the liver at this dose was less selective. The in-vitro effect of MDL 72145 on the soluble enzyme diamine oxidase from rat intestine was 100 fold less potent than that of semicarbazide but about equipotent with semicarbazide on sheep plasma amine oxidase. Overall MDL 72145 was selectively more active against membrane bound SSAO enzymes that deaminate primary monoamines. Although MDL 72145 does inhibit MAO-B activity these results suggest that this compound may be used to study the effect of selective inhibition of SSAO activity on the pharmacological responses of appropriate preparations in-vitro.
腹腔注射MDL 72145((E)-2-(3',4'-二甲氧基苯基)-3-氟烯丙胺)(2.5毫克/千克)一小时后,体外测量的大鼠主动脉和棕色脂肪组织的氨基脲敏感胺氧化酶(SSAO)活性降低至对照值的95%以上,而单胺氧化酶(MAO-A)活性几乎未受影响。该剂量的这种药物对肝脏中胺氧化酶的作用选择性较低。MDL 72145对大鼠肠道可溶性酶二胺氧化酶的体外作用效力比氨基脲低100倍,但对绵羊血浆胺氧化酶的作用与氨基脲相当。总体而言,MDL 72145对脱氨伯单胺的膜结合SSAO酶具有更高的选择性活性。尽管MDL 72145确实抑制MAO-B活性,但这些结果表明,该化合物可用于研究选择性抑制SSAO活性对合适体外制剂药理反应的影响。